FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381337665> ?p ?o ?g. }

• W4381337665 abstract "The DREAM study showed long-term benefits for glucose control in newly diagnosed type 2 diabetes (T2D) patients even after withdrawal of dorzagliatin treatment, a newly approved glucokinase activator for T2D treatment, who were considered to be in the remission for diabetes. The purpose of the current study is to examine the mechanisms of dorzagliatin-induced diabetes remission by evaluating the changes in islet function over time after a period of administering dorzagliatin in high-fat diet (HFD) induced obesity and diabetes mouse models. Diabetes mice were generated after 7 months of HFD, then received dorzagliatin or vehicle controls via oral gavage once a day for 19 days (8 days of 30 mg/Kg and 11 days of 15 mg/Kg). After drug withdrawal, one group of mice remained in HFD and another group changed to a normal diet. Islets were then isolated at different time points after drug withdrawal, and the serum and liver were collected for evaluation. The glucose ramp-stimulated insulin secretion (GSIS) was evaluated in islet perifusion. Gene expression was measured by qPCR in islets and by RNA-seq in the liver. Compared to normal mouse islets, HFD-induced diabetic islets in vehicle groups have impaired GSIS with about 40% reduction in maximum insulin secretion. In contrast, GSIS was fully recovered to the levels of normal islets in 10, 18 and 38 days after dorzagliatin withdrawal, but returned to defective GSIS levels after 45 days of drug discontinuation. In addition, islet GSIS can be fully recovered after 80 days of diet change. In conclusion, the defective GSIS in HFD-induced diabetes mouse islets is reversible and can be fully restored by dorzagliatin even after a long period of drug withdrawal while still remaining in HFD. The mechanisms are likely due to increased glucokinase gene expression caused by a short treatment of dorzagliatin. Diet change alone can recover islet function but requires weight reduction and a longer duration. Disclosure D. Han: Employee; Nanjing AscendRare Pharmaceutical Technology. S. Meng: Employee; Nanjing AscendRare Pharmaceutical Technology. X. Zhou: Employee; Nanjing AscendRare Pharmaceutical Technology. R. Li: Employee; Nanjing AscendRare Pharmaceutical Technology. C. Li: Employee; Hua Medicine, Nanjing AscendRare Pharmaceutical Technology." @default.
• W4381337665 created "2023-06-21" @default.
• W4381337665 creator A5023162733 @default.
• W4381337665 creator A5069616452 @default.
• W4381337665 creator A5078790153 @default.
• W4381337665 creator A5084270691 @default.
• W4381337665 creator A5085663161 @default.
• W4381337665 date "2023-06-20" @default.
• W4381337665 modified "2023-09-24" @default.
• W4381337665 title "297-LB: Dorzagliatin, a Glucokinase Activator, Repairs Defective Islet Function in High-Fat Diet-Induced Diabetic Mice" @default.
• W4381337665 doi "https://doi.org/10.2337/db23-297-lb" @default.
• W4381337665 hasPublicationYear "2023" @default.
• W4381337665 type Work @default.
• W4381337665 citedByCount "0" @default.
• W4381337665 crossrefType "journal-article" @default.
• W4381337665 hasAuthorship W4381337665A5023162733 @default.
• W4381337665 hasAuthorship W4381337665A5069616452 @default.
• W4381337665 hasAuthorship W4381337665A5078790153 @default.
• W4381337665 hasAuthorship W4381337665A5084270691 @default.
• W4381337665 hasAuthorship W4381337665A5085663161 @default.
• W4381337665 hasConcept C126322002 @default.
• W4381337665 hasConcept C134018914 @default.
• W4381337665 hasConcept C165220095 @default.
• W4381337665 hasConcept C170493617 @default.
• W4381337665 hasConcept C2777180221 @default.
• W4381337665 hasConcept C2778715236 @default.
• W4381337665 hasConcept C2779306644 @default.
• W4381337665 hasConcept C555293320 @default.
• W4381337665 hasConcept C71924100 @default.
• W4381337665 hasConcept C88045685 @default.
• W4381337665 hasConcept C98335778 @default.
• W4381337665 hasConceptScore W4381337665C126322002 @default.
• W4381337665 hasConceptScore W4381337665C134018914 @default.
• W4381337665 hasConceptScore W4381337665C165220095 @default.
• W4381337665 hasConceptScore W4381337665C170493617 @default.
• W4381337665 hasConceptScore W4381337665C2777180221 @default.
• W4381337665 hasConceptScore W4381337665C2778715236 @default.
• W4381337665 hasConceptScore W4381337665C2779306644 @default.
• W4381337665 hasConceptScore W4381337665C555293320 @default.
• W4381337665 hasConceptScore W4381337665C71924100 @default.
• W4381337665 hasConceptScore W4381337665C88045685 @default.
• W4381337665 hasConceptScore W4381337665C98335778 @default.
• W4381337665 hasIssue "Supplement_1" @default.
• W4381337665 hasLocation W43813376651 @default.
• W4381337665 hasOpenAccess W4381337665 @default.
• W4381337665 hasPrimaryLocation W43813376651 @default.
• W4381337665 hasRelatedWork W1973049774 @default.
• W4381337665 hasRelatedWork W1985965417 @default.
• W4381337665 hasRelatedWork W1986775667 @default.
• W4381337665 hasRelatedWork W2030768859 @default.
• W4381337665 hasRelatedWork W2031301348 @default.
• W4381337665 hasRelatedWork W2064538767 @default.
• W4381337665 hasRelatedWork W2069827981 @default.
• W4381337665 hasRelatedWork W2142140377 @default.
• W4381337665 hasRelatedWork W2153742172 @default.
• W4381337665 hasRelatedWork W2889695791 @default.
• W4381337665 hasVolume "72" @default.
• W4381337665 isParatext "false" @default.
• W4381337665 isRetracted "false" @default.
• W4381337665 workType "article" @default.